慢性肾脏病贫血的规范化治疗

Standardized treatment of chronic renal anemia

贫血是慢性肾脏病常见的并发症之一,主要原因为促红细胞生成素(EPO)生成不足和铁缺乏,是肾脏功能下降的一种表现,因此,EPO和铁剂是治疗慢性肾性贫血的主要药物。本文综述了近年来慢性肾脏疾病贫血的评估及血红蛋白的治疗目标,EPO和铁剂治疗的指征、用法、疗效评价和注意事项以及新型促红细胞生成药物的研究进展,以期提高对慢性肾脏病贫血规范化治疗的认识。

Anemia is one of the common complications of chronic kidney disease（CKD）and is mostly due to deficiency of erythropoietin（EPO）and iron.It is a ramification of decline in fuctional renal mass.Erythropoiesisstimulating agents（ESA）and iron have been available since decades to treat anemia of CKD.The article reviews the recent evaluation in chronic renal anemia and therapeutic target in hemoglobin,indications,use,efficacy and considerations in EPO and iron therapy,and research progress of new ESA to raise the understanding in standard treatment of chronic renal anemia.